Pacira reported $77.19M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
Astellas Pharma JPY 197B 14.32B Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
J&J USD 5.89B 777M Jun/2025
Ligand Pharmaceuticals USD 20.18M 1.37M Jun/2025
Novo Nordisk 18.85B 2.74B Jun/2025
Pacira USD 77.19M 9.58M Jun/2025
Perrigo USD 273.1M 8.1M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
Supernus Pharmaceuticals USD 62.22M 27.72M Jun/2025
Teva Pharmaceutical Industries USD 959M 40M Jun/2025
Xeris Pharmaceuticals USD 44.39M 35.89M Jun/2025
Zoetis USD 617M 54M Jun/2025